Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.63 |
| ▸ | ABL1 | P00519 | 14/20 | 0.63 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.63 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.63 |
| ▸ | PIK3CG | P48736 | 13/20 | 0.63 |
| ▸ | PRKDC | P78527 | 13/20 | 0.63 |
| ▸ | HCK | P08631 | 13/20 | 0.63 |
| ▸ | EGFR | P00533 | 12/20 | 0.63 |
| ▸ | MTOR | P42345 | 12/20 | 0.63 |
| ▸ | EPHB4 | P54760 | 12/20 | 0.63 |
| ▸ | KDR | P35968 | 11/20 | 0.63 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.63 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.54 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129863 | 0.88 | SRC (0.61) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL130467 | 0.88 | PIK3CD (0.61) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL23917240 | 0.88 | PIK3CD (0.78) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL130513 | 0.83 | SRC (0.79) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL130644 | 0.82 | NUDT14 (0.70) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL23997199 | 0.82 | SRC (0.73) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL128513 | 0.81 | PIK3CD (0.67) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL234181 | 0.80 | SRC (0.80) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL13828397 | 0.79 | PIK3CD (0.61) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL22275940 | 0.77 | SRC (0.54) | SRCABL1PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-06-18 | — | — | US | disclosed |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-04-11 | — | — | US | disclosed |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-26 | — | — | US | disclosed |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-26 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | MAP4K2, MAP3K20, MAP3K1 | SRC 85/4885ABL1 106/4885PIK3CD 288/4885 |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | SRC 285/4885ABL1 334/4885PIK3CD 47/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | SRC 285/4885ABL1 334/4885PIK3CD 47/4885 |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKAR2B | SRC 254/4885ABL1 464/4885PIK3CD 89/4885 |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | SRC 285/4885ABL1 334/4885PIK3CD 47/4885 |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | SRC 285/4885ABL1 334/4885PIK3CD 47/4885 |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | MAP3K1, CSNK1A1, MAP3K2 | SRC 90/4885ABL1 376/4885PIK3CD 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.